Journal article

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3 )

Vincent Leroy, Peter Angus, Jean-Pierre Bronowicki, Gregory J Dore, Christophe Hezode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee, Rafia Bhore, Maria Jesus Jimenez-Exposito, Alexander J Thompson

HEPATOLOGY | WILEY | Published : 2016

Abstract

UNLABELLED: Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination of daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SOF; nucleotide nonstructural protein 5B inhibitor) for 12 weeks previously showed high efficacy (96%) in noncirrhotic genotype 3 infection. The phase III ALLY-3+ study (N = 50) evaluated DCV-SOF with ribavirin (RBV) in treatment-naïve (n = 13) or treatment-experienced (n = 37) genotype 3-infected patients with advanced fibrosis (n = 14) or compensated cirrhosis (n = 36). Patients were randomized 1:..

View full abstract